Medicine
Duavee 20 mg/0.45 mg tablet
Duavee 20 mg/0.45 mg tablet is a prescription medicine containing Bazedoxifene and Estrogens, conjugated for oral use, marketed by Wyeth Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Blisters DUAVEE tablets should be stored at 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Bazedoxifene and Estrogens, conjugated
- Brand
- Duavee
- Strength
- 20 mg/0.45 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 pouch
- Marketing authorisation holder
- Wyeth Pharmaceuticals
- Manufacturer
- Wyeth Pharmaceuticals2 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Blisters DUAVEE tablets should be stored at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature. Protect from moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 October 2013
- Identifiers
- RxCUI 1441392, 1441740DailyMed set ID e16705d8-4472-4f83-96ac-69fa2be066cb, e1b75458-2e5b-46b9-92c6-fa6daba3770fNDC 63539-122, 0008-1123Application NDA022247
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 pouch in 1 carton / 2 blister pack in 1 pouch / 15 tablet, film coated in 1 blister pack | 0008-1123-12 | Wyeth Pharmaceuticals | 3 October 2013 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 3 October 2013 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Bazedoxifene and Estrogens, conjugated is a fixed-dose combination of an estrogen agonist/antagonist and an estrogen. It is available as tablets for oral use. MedsAcross supplies Bazedoxifene and Estrogens, conjugated for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Bazedoxifene and Estrogens, conjugatedFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Duavee prescribing information (US Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Duavee 20 mg/0.45 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.